[1] 桑红,廖万清,陈江汉,等.新生隐球菌产黑素野生株和白化突变株的比较研究[J].中华皮肤科杂志,2000,33(5):347-348.
[2] Maxson ME,Cook E,Casadevall A,et al.The volume and hydration of the Cryptococcus neoformans polysacchatide capsule[J].Fungal Genet Biol,2007,44(3):180-186.
[3] Jesus MD,Nicola AM,Rodrigues ML,et al.Capsular localization of the Cryptococcus neoformans polysaccharide component galactexylomannan[J].Eukaryot Cell,2009,8(1):96-103.
[4] Franzot SP,Salkin IF,Casadevall A.Cryptococcus neoformans var.grubii:separate varietal status for Cryptococcus neoformans serotype A isolates[J].J Clin Microbiol,1999,37(3):838-840.
[5] Okabayashi K,Kano R,Watanabo S,et al.Expression of capsule-associated genes of Cryptococcus neoformans[J].Mycopathologia,2005,160(1):1-7.
[6] Rodrigues ML,Nakayasu ES,Oliveira DL,et al.Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence[J].Eukatyot Cell,2008,7(1):58-67.
[7] Klutts JS,Levery SB,Doering TL.A beta-1,2-xylesyhransferase from Cryptococcus neoformans defines a new family of glycosyl-transferases[J].J Biol Chem,2007,282(24):17890-17899.
[8] 潘炜华,廖万清,刘晓刚,等.绿色荧光蛋白GFP基因与新生隐球菌荚膜基因的融合表达系统[J].中国真菌学杂志,2006,1(4):193-196.
[9] Bar-Peled M,Griffith CL,Ory JJ,et al.Biosynthesis of UDPGIcA,a key metabolite for capsular polyzaccharide synthesis in the pathogenic fungus Cryptococcus neoformans[J].Biochem J,2004,381(pt1):131-136.
[10] Griffith CL,Klutts JS,Zhang L,et al.UDP-glucoso dehydrogenase plays multiple roles in the biology of the pathogenic fungus Cryptococcus neoformans[J].J Biol Chem,2004,279(49):51669-51676.
[11] Moyrand F,Fontaine T,Janbon G.Systematic capsule gone disruption reveals the central role of galactese metabolism on Cryptococcus neoformans virulence[J].Mol Micrebiol,2007,64(3):771-781.
[12] Nimrichter L,Frases S,Cinelli LP,et al.Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations[J].Eukaryot Cell,2007,6(8):1400-1410.
[13] O 'Meata TR,Norton D,Price MS,et al.Interaction of Cryptococcus neoformans Rim101 and protein kinase A regulates capsule[J].PLoS Pathog,2010,6(2):e1000776:1-14.
[14] Yaneda A,Doering TL.A eukaryotic eapsalar polysaccharide is synthesized intracellularly and secreted via exocytosis[J].Mol Biol Cell,2006,17(12):5131-5140.
[15] Rodrigues ML,Nakayasu ES,Oliveira DL,et al.Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence[J].Eukaryot Cell,2008,7(1):58-67.
[16] Nicola AM,Frases S,Casadevall A.Lipophilic dye staining of Cryptococcus neoformans extracellular vesicles and capsule[J].Eukaryot Call,2009,8(9):1373-1380.
[17] Taborda CP,Casadevall A.CR3(CD11b/CD18)and CR4(CD11c/CD18)are involved in complement-independent antibody-mediated phagocytesis of Cryptococcus neoformans[J].Immunity,2002,16(6):791-802.
[18] Gates MA,Kozel TR.Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans[J].Infect Immun,2006,74(6):3096-3106.
[19] Botts MR,Giles SS,Gates MA,et al.Isolation and characterization of Cryptococcus neoformans spores reveal a critical role for capsule biosynthesis genes in spore biogenesis[J].Eukaryot Cell,2009,8(4):595-605.
[20] Barbosa FM,Fonseca FL,Figeeiredo RT,et al.Binding of glucuronoxylomannan to the CD14 receptor in human A549 alveolar cells induces intedeukin-8 preduction[J].Clin Vaccine Immunol,2007,14(1):94-98.
[21] Shea JM,Kechichian TB,Luberto C,et al.The cryptococcal enzyme inositolphosphosphingolipid-phespholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system[J].Infect Immun,2006,74(10):5977-5988.
[22] Moyzand F,Fontaine T,Janbon G.Systematic capsule gone disruption reveals the central role of galactose metabolism on Cryptococcus neoformans virulence[J].Mol Microbiol,2007,64(3):771-781.
[23] Monari C,Bistoni F,Vecchiatelli A.Glueuronoxylomannan exhibits potent immunesuppressive properties[J].FEMS Yeast Res,2006,6(4):537-542.
[24] Villena SN,Pinheiro BO,Pinheiro CS,et al.Capsular polyzaccharides galactoxylomannan and glucaronoxylomannan from Cryptococcus neoformans induce macrophage apoptesis mediated by Fas ligand[J].Cell Microbiol,2008,10(6):1274-1285.
[25] Walenkamp AM,Chaka WS,Verheul AF,et al.Cryptococcus neoformans and its cell wall components induce similar cytokine profiles in human peripheral blood mononuclcar cells despite differences in struture[J].FEMS Immunol Med Microbiol,1999,26(34):309-318.
[26] Cleare W,Mukherjee S,Spitzer ED,et al.Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies[J].Clin Diagn Lab Immunol,1994,1(6):737-740.
[27] Larsen RA,Pappas PG,Perfect J,et al.Phase Ⅰ evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18 B7 in subjects with treated cryptecoccal meningitis[J].Antimicrob Agents Chemother,2005,49(3):952-958.
[28] Rivera J,Casadevall A.Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans[J].J Immunol,2005,174(12):8017-8026.
[29] Beeubouwer DO,Shapiro S,Feldmesser M,et al.Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans[J].Infect Immun,2001,69(10):6445-6455.
[30] Taborda CP,Rivera J,Zaragoza O,et al.More is not necessarily better:prozone-like effects in passive immunization with IgG[J].J Immunol,2003,170(7):3621-3630.
[31] Detta K,Lees A,Pirofski L.Therapeutic efficacy of a conjugate vaccine containing a peptide mimotopo of cryptecoccal capsular polysaccharide glucuronoxylomannan[J].Clin Vaccine Immunol,2008,15(8):1176-1187. |
